115 related articles for article (PubMed ID: 12115341)
1. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.
Wang J; Buchholz TA; Middleton LP; Allred DC; Tucker SL; Kuerer HM; Esteva FJ; Hortobagyi GN; Sahin AA
Cancer; 2002 Jun; 94(12):3107-14. PubMed ID: 12115341
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
[TBL] [Abstract][Full Text] [Related]
3. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Zhang F; Yang Y; Smith T; Kau SW; McConathy JM; Esteva FJ; Kuerer HM; Symmans WF; Buzdar AU; Hortobagyi GN; Pusztai L
Cancer; 2003 Apr; 97(7):1758-65. PubMed ID: 12655533
[TBL] [Abstract][Full Text] [Related]
4. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
5. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
6. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
[TBL] [Abstract][Full Text] [Related]
8. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
9. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
13. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
14. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.
Petrarca CR; Brunetto AT; Duval V; Brondani A; Carvalho GP; Garicochea B
Clin Breast Cancer; 2011 Apr; 11(2):129-34. PubMed ID: 21569999
[TBL] [Abstract][Full Text] [Related]
15. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
Petit T; Borel C; Ghnassia JP; Rodier JF; Escande A; Mors R; Haegelé P
Clin Cancer Res; 2001 Jun; 7(6):1577-81. PubMed ID: 11410493
[TBL] [Abstract][Full Text] [Related]
17. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
18. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
19. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
